Show simple item record

dc.contributor.authorCrommelin, Daan J. A.
dc.contributor.authorSindelar, Robert D.
dc.contributor.authorMeibohm, Bernd
dc.date.accessioned2020-05-08T10:01:17Z
dc.date.available2020-05-08T10:01:17Z
dc.date.issued2019
dc.identifier.isbn978-3-030-00710-2
dc.identifier.urihttp://ir.mksu.ac.ke/handle/123456780/6045
dc.description.abstractOver the past 30 years, the share of biotechnologically derived drug products in the arsenal of medicinal products has been growing steadily. These drug products include proteins, such as monoclonal antibodies, antibody fragments, endogenous or modified hormones, and growth factors, as well as antisense oligonucleotides, RNA, DNA preparations for gene therapy, and stem cell therapies. In 2017, 12 out of the 46 approved marketing authorizations for new molecular entities by the US Food and Drug Administration (FDA) were biotech products, mainly from the monoclonal antibody family (Mullard 2018). Drug products such as epoetin-α (Epogen®, Eprex®, Procrit®), interferon-α (Intron®A, Roferon®A) and interferon-β (Avonex®, Rebif®, Betaseron®), anti-TNF-α agents, etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), bevacizumab (Avastin®), and trastuzumab (Herceptin®) are all examples of highly successful biotech drugs that have revolutionized the pharmacotherapy of previously unmet medical needs. And, last but not least, biotech drugs also have a major socioeconomic impact. In 2017, 7 of the 10 top selling drugs in the world were biotechnologically derived drug products, with sales varying between 5–16 billion US dollars, totaling 75 billion dollars. The revenues of biotechnology-based medication are annually growing at a 10% pace and will reach 300 billion US dollars in 2021, i.e., one third of the total global revenues for brand medicines in that year (IFPIA 2017). The techniques of biotechnology are a driving force of modern drug discovery as well. Due to the rapid growth in the importance of biopharmaceuticals and the techniques of biotechnologies to modern medicine and the life sciences, the field of pharmaceutical biotechnology has become an increasingly important component in the education of today’s and tomorrow’s pharmacists and pharmaceutical scientists. We believe that there is a critical need for an introductory textbook on Pharmaceutical Biotechnology that provides well-integrated, detailed coverage of both the relevant science and clinical application of pharmaceuticals derived by biotechnology. Previous editions of the textbook Pharmaceutical Biotechnology: Fundamentals and Applications have provided a well-balanced framework for education in various aspects of pharmaceutical biotechnology, including production, dosage forms, administration, economic and regulatory aspects, and therapeutic applications. Rapid growth and advances in the field of pharmaceutical biotechnology, however, made it necessary to revise this textbook in order to provide up-to- date information and introduce readers to the cutting-edge knowledge and technology of this field. This fifth edition of the textbook Pharmaceutical Biotechnology: Fundamentals and Applications builds on the successful concept used in the preceding editions and further expands its availability as electronic versions of the full book as well as individual chapters are readily available and downloadable through online platforms.en_US
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.titlePharmaceutical Biotechnologyen_US
dc.title.alternativeFundamentals and Applicationsen_US
dc.typeBooken_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record